Healis Therapeutics selected to speak on opening day of 2024 Biotech Showcase in San Francisco
December 05, 2023 08:00 ET
|
Healis Therapeutics
Healis Co-Founders Sebastian De Beurs and Dr. Eric Finzi will be presenting on the company's neurotherapeutics pipeline and clinical development.
Aegis AI: The Revolutionary AI Tool Driving On-chain Security
December 04, 2023 13:00 ET
|
Aegis AI
London , Dec. 04, 2023 (GLOBE NEWSWIRE) -- Smart contract security has posed to be one of the most crucial elements of blockchain technology. Millions of dollars have been lost to malicious attacks...
Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity
December 04, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating Preclinical data show magnesium-potentiation...
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December
November 28, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates,...
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
November 27, 2023 09:00 ET
|
Biodexa Pharmaceuticals PLC
Cardiff , Nov. 27, 2023 (GLOBE NEWSWIRE) -- 27 November 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to...
SOHM Announces New CDMO GMP Manufacturing Facility in Carlsbad, California
November 21, 2023 09:30 ET
|
SOHM, Inc.
CHINO HILLS, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs...
Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia
November 15, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Topline results expected late December 2023 RESILIENT is expected to be the final efficacy trial required for submission of a New Drug Application to FDA; first successful Phase 3 trial,...
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment
November 15, 2023 02:00 ET
|
T-Therapeutics
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis...
Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder
November 13, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Children with Autism Spectrum Disorder are at Risk for Low Bone Density Preliminary Data Suggest that the Administration of Oxytocin May Favorably Impact Bone Formation and Strength Recent...
CARGO Therapeutics Announces Pricing of Initial Public Offering
November 09, 2023 20:07 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announce Pricing of IPO